Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights BOSTON, Mass., May 9, 2024 -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells, today provided a business and financial update for the first quarter 2024. Recent Business Highlights • CUE-101 abstract accepted for an oral presentation and poster presentation at the upcoming 2024 Amer ...